MCMV-based vaccine vectors expressing full-length viral proteins provide long-term humoral immune protection upon a single-shot vaccination
Open Access
- 7 January 2022
- journal article
- research article
- Published by Springer Nature in Cellular & Molecular Immunology
- Vol. 19 (2) , 234-244
Abstract
Global pandemics caused by influenza or coronaviruses cause severe disruptions to public health and lead to high morbidity and mortality. There remains a medical need for vaccines against these pathogens. CMV (cytomegalovirus) is a β-herpesvirus that induces uniquely robust immune responses in which remarkably large populations of antigen-specific CD8+ T cells are maintained for a lifetime. Hence, CMV has been proposed and investigated as a novel vaccine vector for expressing antigenic peptides or proteins to elicit protective cellular immune responses against numerous pathogens. We generated two recombinant murine CMV (MCMV) vaccine vectors expressing hemagglutinin (HA) of influenza A virus (MCMVHA) or the spike protein of severe acute respiratory syndrome coronavirus 2 (MCMVS). A single injection of MCMVs expressing either viral protein induced potent neutralizing antibody responses, which strengthened over time. Importantly, MCMVHA-vaccinated mice were protected from illness following challenge with the influenza virus, and we excluded that this protection was due to the effects of memory T cells. Conclusively, we show here that MCMV vectors induce not only long-term cellular immunity but also humoral responses that provide long-term immune protection against clinically relevant respiratory pathogens.Keywords
All Related Versions
Funding Information
- China Scholarship Council
- Helmholtz Association (PIE-0008)
This publication has 67 references indexed in Scilit:
- A Cytomegalovirus-based Vaccine Expressing a Single Tumor-specific CD8+ T-cell Epitope Delays Tumor Growth in a Murine Model of Prostate CancerJournal of Immunotherapy, 2012
- Preliminary Assessment of the Efficacy of a T-Cell–Based Influenza Vaccine, MVA-NP+M1, in HumansClinical Infectious Diseases, 2012
- Virus Progeny of Murine Cytomegalovirus Bacterial Artificial Chromosome pSM3fr Show Reduced Growth in Salivary Glands due to a Fixed Mutation of MCK-2Journal of Virology, 2011
- Profound early control of highly pathogenic SIV by an effector memory T-cell vaccineNature, 2011
- An adjuvanted pandemic influenza H1N1 vaccine provides early and long term protection in health care workersVaccine, 2010
- Vaccine Adjuvants: Putting Innate Immunity to WorkImmunity, 2010
- A Spread-Deficient Cytomegalovirus for Assessment of First-Target Cells in VaccinationJournal of Virology, 2010
- Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challengeNature Medicine, 2009
- Targeted Deletion of Regions Rich in Immune-Evasive Genes from the Cytomegalovirus Genome as a Novel Vaccine StrategyJournal of Virology, 2007
- Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjectsJournal of Experimental Medicine, 2005